Share on StockTwits

Momenta Pharmaceuticals (NASDAQ:MNTA) President Craig A. Wheeler sold 1,768 shares of the company’s stock on the open market in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $11.54, for a total value of $20,402.72. Following the completion of the transaction, the president now directly owns 370,518 shares of the company’s stock, valued at approximately $4,275,778. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 3.35% during mid-day trading on Monday, hitting $11.72. The stock had a trading volume of 57,514 shares. Momenta Pharmaceuticals has a 52-week low of $9.85 and a 52-week high of $19.90. The stock’s 50-day moving average is $11.23 and its 200-day moving average is $12.79. The company’s market cap is $603.4 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Thursday, July 31st. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.46) by $0.05. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter in the prior year, the company posted ($0.57) earnings per share. The company’s quarterly revenue was up 151.1% on a year-over-year basis. On average, analysts predict that Momenta Pharmaceuticals will post $-1.14 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on MNTA shares. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $19.20.

Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.